IOVA FY 2012 Earnings — Iovance Biotherapeutics, Inc. Revenue & Financial Results | Market Cap Arena

IOVAIovance Biotherapeutics, Inc.

$2B

FY 2012 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

-$6M

Operating Income

-$8M

Net Income

-$3M

EPS (Diluted)

$-4.14

Cash Flow

Operating Cash Flow

-$2M

Free Cash Flow

-$2M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$29,413

Total Liabilities

$11M

Stockholders' Equity

-$11M

Cash & Equivalents

-$5,000

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	-$6M	-$19M	+66.4%
Operating Income	-$8M	-$21M	+61.7%
Net Income	-$3M	-$26M	+87.1%